AI Engines For more Details: Perplexity Kagi Labs You
Parkinson's Disease: Ethopropazine hydrochloride is used to alleviate some of the symptoms associated with Parkinson's disease, such as tremors, rigidity, and bradykinesia (slowness of movement). It works by acting as a centrally acting anticholinergic agent, blocking the action of acetylcholine in the central nervous system, which helps to rebalance the levels of neurotransmitters.
Extrapyramidal Symptoms: Ethopropazine hydrochloride may also be prescribed to manage extrapyramidal symptoms (EPS) caused by certain medications, particularly antipsychotics. EPS can include dystonia, akathisia, parkinsonism, and tardive dyskinesia. Ethopropazine helps alleviate these symptoms by reducing abnormal muscle contractions and movements.
Muscle Relaxation: The medication's anticholinergic properties contribute to muscle relaxation, which can help reduce muscle stiffness and spasms associated with Parkinson's disease and other movement disorders.
Adjunctive Therapy: Ethopropazine hydrochloride is often used in combination with other medications for Parkinson's disease, such as levodopa/carbidopa or dopamine agonists, to enhance therapeutic effects and improve motor function.
Dosage and Administration: The dosage of ethopropazine hydrochloride may vary depending on the individual patient's response and tolerance. It is typically administered orally in tablet form, with dosing frequency determined by the prescribing healthcare provider.
Side Effects: Common side effects of ethopropazine hydrochloride may include dry mouth, blurred vision, urinary retention, constipation, drowsiness, dizziness, and confusion. These side effects are often dose-related and may improve with dosage adjustments or discontinuation of the medication.
Contraindications: Ethopropazine hydrochloride is contraindicated in individuals with narrow-angle glaucoma, severe gastrointestinal obstruction, urinary retention, and certain other medical conditions. It should be used with caution in elderly patients and those with preexisting cognitive impairment.
Drug Interactions: Ethopropazine hydrochloride may interact with other medications, including anticholinergic agents, antidepressants, antipsychotics, and certain antibiotics. Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Monitoring: Regular monitoring by a healthcare professional is essential to assess treatment efficacy, monitor for adverse effects, and adjust medication dosage as needed.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
ADHD | 3.7 | 0.7 | 4.29 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.5 | -4 |
Allergic Rhinitis (Hay Fever) | 1.5 | 1.5 | |
Allergies | 2.8 | 2.1 | 0.33 |
Allergy to milk products | 0.7 | 0.5 | 0.4 |
Alopecia (Hair Loss) | 1.5 | 1.5 | |
Alzheimer's disease | 2.5 | 4.3 | -0.72 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.5 | 1.1 | 2.18 |
Ankylosing spondylitis | 2.8 | 1.1 | 1.55 |
Anorexia Nervosa | 0.5 | 1.4 | -1.8 |
Antiphospholipid syndrome (APS) | 1.5 | 0.2 | 6.5 |
Asthma | 0.5 | 2 | -3 |
Atherosclerosis | 0.4 | 1.8 | -3.5 |
Atrial fibrillation | 2.5 | 2.2 | 0.14 |
Autism | 7.8 | 7.9 | -0.01 |
Barrett esophagus cancer | 0 | 0.2 | 0 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 1.3 | 0.9 | 0.44 |
Brain Trauma | 0.3 | 0.6 | -1 |
Carcinoma | 2.7 | 2 | 0.35 |
Celiac Disease | 2.3 | 2.6 | -0.13 |
Cerebral Palsy | 0.7 | 0.9 | -0.29 |
Chronic Fatigue Syndrome | 4.4 | 6.5 | -0.48 |
Chronic Kidney Disease | 1.7 | 1.9 | -0.12 |
Chronic Lyme | 0.6 | -0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.6 | 0.67 |
Chronic Urticaria (Hives) | 0.4 | 2.9 | -6.25 |
Coagulation / Micro clot triggering bacteria | 0.8 | 0.6 | 0.33 |
Colorectal Cancer | 3.4 | 0.8 | 3.25 |
Constipation | 1.6 | 0.3 | 4.33 |
Coronary artery disease | 1.3 | 0.7 | 0.86 |
COVID-19 | 8.8 | 13.4 | -0.52 |
Crohn's Disease | 6.2 | 5.2 | 0.19 |
cystic fibrosis | 0.1 | 0.6 | -5 |
deep vein thrombosis | 0.1 | 0.4 | -3 |
Depression | 8.1 | 7.7 | 0.05 |
Dermatomyositis | 0.2 | 0.2 | |
Eczema | 0.5 | 1.7 | -2.4 |
Endometriosis | 1.9 | 0.7 | 1.71 |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 2.7 | 3.6 | -0.33 |
Fibromyalgia | 1.8 | 3.4 | -0.89 |
Functional constipation / chronic idiopathic constipation | 4.5 | 4 | 0.13 |
gallstone disease (gsd) | 0.8 | 0.1 | 7 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 0.6 | 2.33 |
Generalized anxiety disorder | 0.7 | 1 | -0.43 |
Glioblastoma | 0.2 | -0.2 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.3 | 0.6 | 1.17 |
Halitosis | 0.5 | 0.2 | 1.5 |
Hashimoto's thyroiditis | 1.3 | 0.7 | 0.86 |
Hidradenitis Suppurativa | 0.4 | 0 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.7 | 0.9 | 0.89 |
hypercholesterolemia (High Cholesterol) | 0.5 | 1 | -1 |
hyperglycemia | 0 | 2.6 | 0 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.1 | 3.6 | -0.71 |
Hypothyroidism | 0.9 | -0.9 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 4.6 | -4.6 | |
Inflammatory Bowel Disease | 3.4 | 8.2 | -1.41 |
Insomnia | 0.9 | 0.7 | 0.29 |
Intelligence | 1.5 | 1 | 0.5 |
Intracranial aneurysms | 1.3 | 0.3 | 3.33 |
Irritable Bowel Syndrome | 3.8 | 5.2 | -0.37 |
Liver Cirrhosis | 3.3 | 2.1 | 0.57 |
Long COVID | 8.1 | 5.6 | 0.45 |
Low bone mineral density | 0.6 | -0.6 | |
Lung Cancer | 1 | 1.2 | -0.2 |
ME/CFS with IBS | 0.4 | 1.8 | -3.5 |
ME/CFS without IBS | 1.5 | 1.5 | 0 |
Menopause | 1 | 1 | |
Metabolic Syndrome | 6.9 | 7.2 | -0.04 |
Mood Disorders | 10.2 | 7.9 | 0.29 |
multiple chemical sensitivity [MCS] | 1.3 | 0.2 | 5.5 |
Multiple Sclerosis | 4.2 | 5.5 | -0.31 |
Multiple system atrophy (MSA) | 1.7 | 0.3 | 4.67 |
Neuropathy (all types) | 0.9 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 4 | -1.35 |
Obesity | 6 | 4.5 | 0.33 |
obsessive-compulsive disorder | 6.5 | 4.5 | 0.44 |
Osteoarthritis | 1.2 | 0.1 | 11 |
Osteoporosis | 0.9 | 1.6 | -0.78 |
pancreatic cancer | 0.7 | 0.7 | |
Parkinson's Disease | 3.4 | 2.9 | 0.17 |
Polycystic ovary syndrome | 2.3 | 1.3 | 0.77 |
Postural orthostatic tachycardia syndrome | 0.5 | -0.5 | |
Premenstrual dysphoric disorder | 0.5 | 0.5 | 0 |
primary biliary cholangitis | 1.3 | -1.3 | |
Psoriasis | 2.6 | 4.5 | -0.73 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.3 | 2.9 | 0.83 |
Rosacea | 0.1 | 0.1 | 0 |
Schizophrenia | 4.9 | 0.8 | 5.13 |
scoliosis | 0.5 | 0.4 | 0.25 |
Sjögren syndrome | 2.5 | 2.7 | -0.08 |
Sleep Apnea | 0.7 | 1.5 | -1.14 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 1.7 | 2.8 | -0.65 |
Systemic Lupus Erythematosus | 4.3 | 0.9 | 3.78 |
Tic Disorder | 1.6 | 1.3 | 0.23 |
Tourette syndrome | 0.5 | 0.5 | 0 |
Type 1 Diabetes | 4.5 | 1.4 | 2.21 |
Type 2 Diabetes | 7.9 | 7.5 | 0.05 |
Ulcerative colitis | 1 | 7.7 | -6.7 |
Unhealthy Ageing | 4.9 | 2.5 | 0.96 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.